1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. MBX BIOSCIENCES INC.

MBX Biosciences Inc.

XNAS: MBX

Download real time

7.89 -0.08 (-1.00%)

New 52W Low today

259.1K XNAS Volume

XNAS 21 Mar, 2025 4:01 PM (EDT)

Watchlist

Portfolio

Share
0S
14W
5O
0T
263.7

Market Cap

Below industry Median
-

PE TTM

-

PEG TTM

1

Price to Book

Below industry Median
-

Beta 1Year

Board Meeting
The next board meeting for MBX Biosciences Inc. is on 31 Mar 2025 for the purpose of MBX Biosciences Inc Annual Report for 2024 See details


Insider Trading disclosures for MBX Biosciences Inc.

The latest disclosure was made by Carl L. Gordon in MBX Biosciences Inc. where a trade of 94,100 Common Stock done at an average price of $10.8 was reported to US exchanges on Feb. 14, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 10.84 per share. 14 Feb 2025 94,100 747,887 - 10.8 1,020,044 Common Stock
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 10.84 per share. 14 Feb 2025 49,070 3,255,000 - 10.8 531,919 Common Stock
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 9.85 per share. 14 Feb 2025 29,540 3,205,930 - 9.9 290,969 Common Stock
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 9.90 per share. 14 Feb 2025 17,962 3,176,390 - 9.9 177,824 Common Stock
Salomon Azoulay Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 90,000 90,000 - - Stock Option (Right to Buy)
Peter Kent Hawryluk Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 243,000 243,000 - - Stock Option (Right to Buy)
Peter Kent Hawryluk Director, President & CEO Purchase of securities on an exchange or from another person at price $ 10.69 per share. 03 Feb 2025 50,000 448,277 - 10.7 534,500 Common Stock
Richard B. Bartram Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 03 Feb 2025 95,000 95,000 - - Stock Option (Right to Buy)
James M. Cornelius Director 16 Sep 2024 102,082 102,082 - - Common Stock
James M. Cornelius Director 16 Sep 2024 994,069 0 - - Series A Convertible Preferred Stock
Patrick J. Heron Director, Ten Percent Owner 16 Sep 2024 3,927,774 3,927,774 - - Common Stock
Patrick J. Heron Director, Ten Percent Owner 16 Sep 2024 18,922,852 0 - - Series A Convertible Preferred Stock
Patrick J. Heron Director, Ten Percent Owner 16 Sep 2024 28,297,265 0 - - Series B Convertible Preferred Stock
Patrick J. Heron Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 16.00 per share. 16 Sep 2024 625,000 4,552,774 - 16 10,000,000 Common Stock
Peter Kent Hawryluk Director, President & CEO 16 Sep 2024 1,396,762 0 - - Series B Convertible Preferred Stock
Peter Kent Hawryluk Director, President & CEO 16 Sep 2024 345,705 0 - - Series A Convertible Preferred Stock
Peter Kent Hawryluk Director, President & CEO 16 Sep 2024 283,846 481,397 - - Common Stock
Peter Kent Hawryluk Director, President & CEO 16 Sep 2024 115,914 398,277 - - Common Stock
Peter Kent Hawryluk Director, President & CEO 16 Sep 2024 2,015,681 0 - - Series A Convertible Preferred Stock
Peter Kent Hawryluk Director, President & CEO 16 Sep 2024 970,873 0 - - Series C Convertible Preferred Stock
Peter Kent Hawryluk Director, President & CEO 16 Sep 2024 76,969 0 - - Series B Convertible Preferred Stock
Tiba Aynechi Director 16 Sep 2024 1,386,335 1,386,335 - - Common Stock
Tiba Aynechi Director Purchase of securities on an exchange or from another person at price $ 16.00 per share. 16 Sep 2024 750,000 2,136,335 - 16 12,000,000 Common Stock
Tiba Aynechi Director 16 Sep 2024 16,666,666 0 - - Series B Convertible Preferred Stock
James M. Cornelius Director 16 Sep 2024 233,192 0 - - Series B Convertible Preferred Stock
Carl L. Gordon Director, Ten Percent Owner 16 Sep 2024 19,587,284 0 - - Series B Convertible Preferred Stock
Carl L. Gordon Director, Ten Percent Owner 16 Sep 2024 12,372,634 0 - - Series A Convertible Preferred Stock
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 16.00 per share. 16 Sep 2024 250,000 653,787 - 16 4,000,000 Common Stock
Carl L. Gordon Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 16.00 per share. 16 Sep 2024 500,000 3,158,428 - 16 8,000,000 Common Stock
Carl L. Gordon Director, Ten Percent Owner 16 Sep 2024 403,787 403,787 - - Common Stock
Carl L. Gordon Director, Ten Percent Owner 16 Sep 2024 2,658,428 2,658,428 - - Common Stock
Carl L. Gordon Director, Ten Percent Owner 16 Sep 2024 4,854,368 0 - - Series C Convertible Preferred Stock
Edward T. Mathers Director, Ten Percent Owner 16 Sep 2024 25,142,840 0 - - Series B Convertible Preferred Stock
Edward T. Mathers Director, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 16.00 per share. 16 Sep 2024 500,000 3,614,486 - 16 8,000,000 Common Stock
Edward T. Mathers Director, Ten Percent Owner 16 Sep 2024 2,091,383 3,114,486 - - Common Stock
Edward T. Mathers Director, Ten Percent Owner 16 Sep 2024 1,023,103 1,023,103 - - Common Stock
Edward T. Mathers Director, Ten Percent Owner 16 Sep 2024 12,299,854 0 - - Series A Convertible Preferred Stock
James M. Cornelius Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 15,963 15,963 - - Stock Option (Right to Buy)
Salomon Azoulay Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 45,011 45,011 - - Stock Option (Right to Buy)
Steven Ryder Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 15,963 15,963 - - Stock Option (Right to Buy)
Peter Kent Hawryluk Director, President & CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 120,436 120,436 - - Stock Option (Right to Buy)
Richard B. Bartram Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 42,578 42,578 - - Stock Option (Right to Buy)
Edward T. Mathers Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 15,963 15,963 - - Stock Option (Right to Buy)
Carl L. Gordon Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 15,963 15,963 - - Stock Option (Right to Buy)
Tiba Aynechi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 15,963 15,963 - - Stock Option (Right to Buy)
Ora H. Pescovitz Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 15,963 15,963 - - Stock Option (Right to Buy)
Patrick J. Heron Director, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Sep 2024 15,963 15,963 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters